Celecoxib nanosuspension: Single-step fabrication using a modified nanoprecipitation method and in vivo evaluation

Drug Delivery and Translational Research

Volumn 4, Issue 4, 2014, Pages 365-376

  Malkani, Anju ^a   Date, Abhijit A ^b   Hegde, Darshana ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

^b CREIGHTON UNIVERSITY   (United States)

Author keywords

Celecoxib; Labrafil 1944 CS; Nanoprecipitation; Nanosuspension; Solutol HS 15

Indexed keywords

AEROSIL; CELECOXIB; CREMOPHOR; LABRAFIL M 1944; LUTROL F 127; LUTROL F 68; MACROGOL DERIVATIVE; MIGLYOL; MIGLYOL 810; NANOPARTICLE; OLEOYL MACROGOL GLYCERIDE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPON 90; POLOXAMER; POLYSORBATE 20; POLYSORBATE 80; POTASSIUM DIHYDROGEN PHOSPHATE; SOLUTOL HS 15; SORBITAN LAURATE; SORBITAN OLEATE; SURFACTANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLLOID; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; EVALUATION STUDY; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; NANOPRECIPITATION; NANOSUSPENSION; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; RAT; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

EID: 84904514179     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-014-0201-3     Document Type: Article

References (35)

1. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47: 3-19.
2. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2004;56: 827-40.
3. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006;62: 3-16.
4. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 2003;18: 113-20.
5. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3: 785-96.
6. Möschwitzer J, Achleitner G, Pomper H, Müller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm. 2004;58: 615-9.
7. Liu Y, Huang L, Liu F. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol Pharm. 2010;7: 863-9.
8. Kobierski S, Ofori-Kwakye K, Müller RH, Keck CM. Resveratrol nanosuspensions for dermal application-production, characterization, and physical stability. Pharmazie. 2009;64: 741-7.
9. Pardeike J, Müller RH. Dermal and ocular safety of the new phospholipase A2 inhibitors PX-18 and PX-13 formulated as drug nanosuspension. J Biomed Nanotechnol. 2009;5: 437-44.
10. Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007;340: 126-33.
11. Chiang PC, Alsup JW, Lai Y, Hu Y, Heyde BR, Tung D. Evaluation of aerosol delivery of nanosuspension for pre-clinical pulmonary drug delivery. Nanoscale Res Lett. 2009;4: 254-61.
12. Shubar HM, Lachenmaier S, Heimesaat MM, Lohman U, Mauludin R, Mueller RH, et al. SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers. J Drug Target. 2011;19: 114-24.
13. Sjöström B, Kronberg B, Carlfors J. A method for the preparation of submicron particles of sparingly water-soluble drugs by precipitation in oil-in-water emulsions. I: influence of emulsification and surfactant concentration. J Pharm Sci. 1993;82: 579-83.
14. Sjöström B, Bergenståhl B, Kronberg B. A method for the preparation of submicron particles of sparingly water-soluble drugs by precipitation in oil-in-water emulsions. II: influence of the emulsifier, the solvent, and the drug substance. J Pharm Sci. 1993;82: 584-9.
15. Trotta M, Gallarate M, Pattarino F, Morel S. Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. J Control Release. 2001;76: 119-28.
16. Dolenc A, Kristl J, Baumgartner S, Planinsek O. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm. 2009;376: 204-12.
17. Xia D, Quan P, Piao H, Piao H, Sun S, Yin Y, et al. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci. 2010;40: 325-34.
18. Shekunov BY, Chattopadhyay P, Seitzinger J, Huff R. Nanoparticles of poorly water-soluble drugs prepared by supercritical fluid extraction of emulsions. Pharm Res. 2006;23: 196-204.
19. Trotta M, Gallarate M, Carlotti ME, Morel S. Preparation of griseofulvin nanoparticles from water-dilutable microemulsions. Int J Pharm. 2003;254: 235-42.
20. Margulis-Goshen K, Kesselman E, Danino D, Magdassi S. Formation of celecoxib nanoparticles from volatile microemulsions. Int J Pharm. 2010;393: 230-7.
21. Ali HS, York P, Blagden N. Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. Int J Pharm. 2009;375: 107-13.
22. Subramanian N, Ray S, Ghosal SK, Bhadra R, Moulik SP. Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull. 2004;27: 1993-9.
23. Nagarsenker MS, Joshi MS. Celecoxib-cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage. Drug Dev Ind Pharm. 2005;31: 169-78.
24. Liu Y, Sun C, Hao Y, Jiang T, Zheng L, Wang S. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles. J Pharm Pharm Sci. 2010;13: 589-606.
25. Margulis-Goshen K, Weitman M, Major DT, Magdassi S. Inhibition of crystallization and growth of celecoxib nanoparticles formed from volatile microemulsions. J Pharm Sci. 2011;100: 4390-400.
26. Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm. 2008;346: 124-32.
27. Higuchi WI, Misra J. Physical degradation of emulsions via the molecular diffusion route and the possible prevention thereof. J Pharm Sci. 1962;51: 459-66.
28. Kabalnov AS, Pertzov AV, Shchukin ED. Ostwald ripening in two-component disperse phase systems: application to emulsion stability. Colloids Surf. 1987;24: 19-32.
29. Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir. 2006;22: 906-10.
30. Balakrishnan P, Lee BJ, Oh DH, Kim JO, Lee YI, Kim DD, et al. Enhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systems. Int J Pharm. 2009;374: 66-72.
31. Yoo HS. Preparation of biodegradable polymeric hollow microspheres using O/O/W emulsion stabilized by Labrafil. Colloids Surf B: Biointerfaces. 2006;52: 47-51.
32. Wang S, Sun M, Ping Q. Enhancing effect of Labrafac Lipophile WL 1349 on oral bioavailability of hydroxysafflor yellow A in rats. Int J Pharm. 2008;358: 198-204.
33. Jain AS, Date AA, Nagarsenker MS. Design, characterization and evaluation of anti-epileptic activity of nanoprecipitating preconcnetrate of carbamazepine. Drug Deliv Lett. 2013;3: 61-9.
34. Dixit RP, Nagarsenker MS. Self-nanoemulsifying granules of ezetimibe: design, optimization and evaluation. Eur J Pharm Sci. 2008;35: 183-92.
35. Date AA, Desai N, Dixit R, Nagarsenker MS. Self-nanoemulsifying drug delivery systems (SNEDDS): formulation insights, applications and advances. Nanomedicine (Lond). 2010;5: 1596-616.